Theme: Biological Targets for Advances in Drug Discovery and Logical Design of Therapeutic Agents

Drug Discovery 2016

Renowned Speakers

Drug Discovery 2016

Conferenceseries LLC is delighted to invite you to attend the 2nd International Conference and Expo on Drug Discovery & Designing, one of its remarkable Pharmaceutical conferences, to be held during October 27-29, 2016 in Rome, Italy emphasizing on recent areas of more optimized research techniques like rational and computer aided drug designing for the Discovery, Designing and Development of new drugs than by traditional hit and trial method. To know more about Conference series.

Drug Discovery conferences-2016 focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. Drug Discovery conferences-2016 provides a platform to critically analyze and understand the methods and mechanisms. 

Track 1: Perspective in Drug Discovery

 It is driven by chemistry but increasingly guided by pharmacology and the clinical sciences, drug research has contributed more to the development of medicine during the past century than any other scientific factor. Improving the science of drug development and directive is important in fulfilling the public health. The advent of molecular biology and, in particular, of genomic sciences is having a deep effect on drug discovery. Emphasis is placed on the contrast between the academic and industrial research operating environments, which can influence the efficacy of research collaboration between the two communities, but which plays such an important role in drug innovation. The strategic challenges that research directors face are also emphasized.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

 

Track 2: Cardiovascular Drug Discovery

The organ system which the blood is pumped through the heart and circulates throughout the body through the blood vessels. The cardiovascular system is a shut circulatory system seen in humans and other vertebrates. Its components include the heart, blood vessels, and blood. In humans, there are four heart chambers, i.e. two atria and two ventricles.
Cardiovascular diseases (CVDs) are the major reason of death globally, which are a group of disorders of the heart and blood vessels. Journal of Cardiovascular Diseases & Diagnosis is an Open Access scholarly, academic journal that is concerned with both elementary and translational research, across different disciplines and areas, enhancing insight in cardiovascular disease appliances and the perspective for innovation.
Cardiovascular Drugs refers to Prescription drugs and medicines for diseases concerning to the structure and function of the heart and blood vessels. Studies in these areas include: heart failure, coronary artery disease, high cholesterol, plasma lumps, circulation disorders, and others.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 3: Pharmaceutical Research and Development

In discovery process includes the early phases of research, which are designed to identify an investigational drug and perform primary tests in the lab. This first stage of the process takes approximately three to six years. By the end, researchers hope to identify a promising drug aspirant to further study in the lab and in animal models, and then in people.

These advances offer great promise, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used alongside diagnostics, clinical trial protocols must be modified and enhanced. This may need the use of additional procedures and resources, as well as new or innovative forms of data collection. Moreover, by their very nature, the patient population identified to respond to targeted therapies is narrower, which makes patient recruitment more difficult.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 4: Drug Designing

Drug design is a impressive inventive process of new medication on the basis of biological target. It is also known as rational drug design or rational design. That is the development in medical history in order to yield significant therapeutic response. The drug is an organic molecule, when it is predicament to target site it can either inhibit or activate the function of a biomolecule which effects in therapeutic benefit. The drug design involves the design of such molecules that are similar to the bio molecular target site in shape and charge in order to bind to it. Drug design relies on the knowledge of the three dimensional structure of bimolecular targets.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 5: Pharmacogenomics

Pharmacogenomics (a mixture of pharmacology and genomics) is the study of the role of genetics in drug response. The field of pharmacogenomics is still in its beginning. Its use is currently quite limited, but new approaches are under study in clinical trials. In the upcoming, pharmacogenomics will allow the development of tailored drugs to treat a inclusive range of health problems, including cardiovascular disease, Alzheimer disease, cancer, HIV/AIDS, and asthma.

It deals with the impact of acquired and inherited genetic variation on drug response in patients by correlating gene existence of single-nucleotide polymorphisms with drug absorption , distribution, metabolism and elimination, as well as drug receptor target effects. Pharmacogenomics aims to develop rational means to optimize drug therapy, with esteem to the patients' genotype, to ensure extreme efficacy with minimal adverse effects.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 6: Drug Discovery in Preclinical Research

In the drug development, preclinical development, also named preclinical studies and non clinical studies, is a stage of investigation that begins before clinical trials (testing in humans) can begin, and during which important feasibility, iterative difficult and drug safety data is collected. Preclinical; in the epidemiological triangle can also be defined as "pre-symptomatic stage" which is known to be, "not yet clinical obvious". The main goals of pre-clinical studies are to regulate the safe dosage for First-in-man study and start to assess product's safety profile. Products may include new or repeated or like-kind medical strategies, drugs, gene therapy solutions, etc. On average, only one in every 5,000 compounds that arrives drug discovery to the stage of pre-clinical development becomes an approved drug.

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 7: In silico Drug Discovery

In silico methods can help in classifying drug targets via bioinformatics tools.
They can also be used to analyze the target structures for probable binding/ active sites, generate candidate molecules, check for their drug likeness, berth these molecules with the target, rank them according to their binding affinities, further optimize the molecules to improve binding appearances. The use of computers and computational methods permeates all aspects of drug discovery today and forms the core of structure-based drug design. High-performance computing, data management software and internet are facilitating the access of huge amount of data generated and transforming the massive complex biological data into effective knowledge in modern day drug discovery process. The use of complementary experimental and informatics techniques increases the chance of success in many phases of the discovery process, from the identification of novel targets and elucidation of their functions to the discovery and development of lead compounds with desired properties. Computational tools offer the improvement of delivering new drug candidates more quickly and at a lower cost. Major roles of computation in drug discovery are; (1) Effective screening & de novo design, (2) in silico ADME/T prediction and (3) Advanced techniques for determining protein-ligand binding.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 8: GPCR's Drug Discovery

G protein-coupled receptors (GPCRs) belong to a great domestic of cell surface signaling proteins that have a pivotal role in many biological functions and in multiple diseases, including the development of cancer and cancer metastasis. Naturally, a number of drugs based on GPCRs have been industrialized for such different indications as cardiovascular, metabolic, neurodegenerative, psychiatric, and oncologic diseases. Owing to the restricted structural information on GPCRs, only limited exploration of structure-based drug design has been possible. Current drugs that target GPCRs - many of which have tremendous therapeutic benefits - are directed towards only a few GPCR members. Therefore, huge determinations are currently proceeding to develop new GPCR-based drugs. We review recent findings that present unexpected opportunities to interfere with main tumorigenic signals by manipulating GPCR-mediated pathways. We also discuss current data concerning novel GPCR targets that may provide talented opportunities for drug discovery in cancer prevention and treatment.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 9: Chemoinformatics Drug Discovery

Chemo informatics plays a vital link between imaginary design and in drug design through extraction of information from the data and translate into knowledge. Derivation of information and knowledge is only one aspect of chemoinformatics. The use of consequent knowledge in a design and selection support role is an important part of the drug design cycle. The main processes within drug discovery are lead documentation, where a lead is something that has activity in the low micro molar range, and lead optimization, which is the process of transforming a lead into a drug candidate. Chemo informatics methods can be used proactively to designing and sieve the most appropriate compounds to work within the real world.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 10: CNS Drug Discovery

The universal market for therapies for central nervous system (CNS) disorders was valued at around US dollars 15 billion in 2011, and is set to raise sharply in the years ahead. This is because of a marked increase in the number of persons aged over 65 (the "baby boomer" effect), which will lead to increased demand for more safe and effective medicines for CNS disorders. 1) how to identify and confirm targets for potential CNS drugs; 2) how to assess brain penetration (both in vitro and in vivo); 3) how to develop in silico methodologies to predict blood-brain barrier penetration; 4) how to evaluate therapeutic efficacy (both in vitro and in vivo); 5) how to establish reliable biomarkers to guide decision making; and 6) how to efficiently apply magnetic resonance imaging to CNS drug discovery.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 11: Proteomics Drug Discovery

Proteins are the major targets of drug discovery. Most large pharmaceutical companies now have a proteomics-oriented biotech or academic companion or have started their own proteomics division. Common applications of proteomics in the drug manufacturing include target identification and validation, identification of efficacy and toxicity biomarkers from readily accessible biological fluids, and studies into mechanisms of drug action or toxicity. Target identification and validation involves identifying proteins whose expression levels or activities change in disease states. These proteins may help as potential therapeutic targets or may be used to classify patients for clinical trials. Proteomics technologies may also support identify protein-protein interactions that influence either the disease state or the proposed therapy. Efficiency biomarkers are used to assess whether target modulation has occurred.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 12: Antibiotics Drug Discovery

Antibodies are the elements that are produced by the body to act against antigens or harmful substances that may affect the health of the person. Antibodies are distinct chemicals and proteins produced by the human body in order to round beside the disease causing bacteria. Antibiotics are chemicals substances that are produced from microorganisms which are capable of stopping and prevent the growth of disease causing bacteria.
Antibiotics and Antibodies have different chemical structures. Each antibody molecule contains two large proteins called heavy chains that further bind to double smaller proteins called light chains. Antibiotics may include extensive range of structures, including series of chemical rings, and do not show the same structural regularity as antibodies.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 13: Fragment-Based Drug Discovery

Fragment-based lead finding (FBLD) also known as fragment-based drug discovery (FBDD) is a method used for finding lead complexes as part of the drug discovery process. It is based on identifying small chemical fragments, which may bind only weakly to the biological target, and then rising them or combining them to produce a lead with a higher affinity. FBLD can be linked with high-throughput screening (HTS). In HTS, libraries with up to millions of compounds, with molecular weights of around 500 Da, are screened, and nanomolar binding affinities are sought. In contrast, in the early phase of FBLD, libraries with a few thousand compounds with molecular weights of around 200 Da may be screened, and millimolar affinities can be measured as useful and drug discovery services. 

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 14: Computer Aided Drug Designing (CADD)

Drug design through computer, a latest, very effective technique in modern arena. Now a days Computer Aided Drug Design (CADD) tools are cast-off in nanotechnology, molecular biology, biochemistry etc. The main benefit of the CADD is total effective in research and development of drugs. There are wide ranges of software are used in CADD, Grid computing, window created general PBPK/PD  modelling software, PKUDDS for structure based drug design,APIS, JAVA, Perl and Python, CADD as well as software including software libraries. There are different techniques used in CADD visualization, homology, molecular vibrant, energy minimization molecular docking, QSAR etc. Drug design conference-2016 provides a stage to critically analyze and understand the methods and mechanisms and Computer aided drug design is applicable in Cancer disease, conveyance of drug to specific site in body, data collections and storages of organics and biological.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 15: Bio Markers in Drug Designing

Biomarkers assist the characterization of patient populations and quantization of the extent to which new drugs reach intended targets, change proposed pathophysiological mechanisms and achieve clinical outcomes. It is anticipated that disease initiation and progression is verbalized by an understandable set of acquired capabilities. Knowledge of the molecular events connected with these acquired capabilities will allow the development of targeted agents coupled with new biomarkers for the prevention of cancer progression. This will have a profound influence on how drugs are developed, permitted, and used by the health community. Biomarkers can stratify patient populations or quantify drug benefit in primary inhibition or disease-modification studies in poorly served areas such as neurodegenaration and cancer. Clinically useful biomarkers are required to advise regulatory and therapeutic decision making regarding candidate drugs and their signs in order to benefit bring new medicines to the right patients faster than they are today.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 16: Ligand Based Drug Discovery

Ligand based drug designs can be used to enhance a lead compound's binding affinity, specificity to a target of interest while increasing efficacy parameters, by eliminating unwanted properties to yield more efficient candidates. Such strategies have marvellous potential to save time and money to identify a new drug candidate compared to high complete put screening (HTS). 3D Structural information of the drug target is not needed but relies on knowledge of small molecules and their binding potencies to the drug target of interest. Provides predictive models suitable for lead identification & optimization.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 17: Structure Based Drug Design

Structure built drug design is the process of designing a chemical structure with the objective of identifying a compound which uniforms for clinical tests. The process involves how that shapes and charges to interact with biological target in demand to yield therapeutic activity. Structure based drug design based on three dimensional structures strictly.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

.

Track 18: Screening and Drug Design

The process of screening is a computational technique playing a major role in drug discovery process. It helps to search small molecules to find the structures which likely bind or interact with drug target.  It is also defined as "automatically estimating exact large collections of compounds" using computer programs. As the accuracy of this method is increased it is widely using in drug design process.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 19: In Silico Methods

In silico techniques with use of bioinformatics are in increasing demand in drug discovery and development that can identify and investigate active sites and suggest potential drug molecules that can bind to these sites specifically. They analyze the target structures for probable binding sites, generate candidate molecules, check for their drug likeness, dock these molecules with the target, abundant them conferring to their binding affinities, further optimize the molecules to improve binding characteristics.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 20: Computational chemistry

In pharmaceutical industry, a major employer of computational chemists, has historically focused on the discovery and design of new small-molecular therapeutics. Recently, but, there is a trend to apply computational chemistry and cheminformatics (a field that syndicates laboratory data, chemical modeling, and information science methods) to process development, analytical chemistry, and biologics (medicinal products manufactured using or extracted from biological sources). Computational chemists use mathematical algorithms, statistics, and large databases to integrate chemical theory and modeling with trial observations. Some computational chemists create models and simulations of physical processes, and others use statistics and data analysis procedures to extract useful information from large bodies of data. Advances in computer visualization abilities make it possible for the computational chemist to present complex analyses in a readily logical form, which they can use to design trials and new materials and validate the results.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 21: Drug Delivery using Nanotechnology

Nanotechnology contains the engineering of functional systems at the molecular scale which are characterized by unique physical, optical and electronic structures that are attractive for disciplines ranging from materials science to biomedicine. The use of nanotechnology in drug development is the emerging process where the nanoparticles used to deliver the drug to the specific cell which is diseased. By this technology the particles which are engineered in such a way that they can attract to the diseased cell and allows treatment to the particular cell directly. Through this unique technique can minimize the damage of healthy cells in the body.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 22: Scaffold Based Drug Discovery

Small organic molecules can be potent tools for impacting biology and medicine, functioning as both therapeutics and as reviews that help to illuminate the macromolecules regulating biological processes. Yet, despite advances on many fronts, including the ability of synthetic chemists to prepare books containing thousands of compounds efficiently, the ability to make critical findings pertinent to disease remains a slow and, arguably, serendipitous one. high-through put synthesis and screening of compound collections through phenotypic or biochemical assays often yields disappointing results in terms of a lack of specific, useful compounds discovered, relative to the high cost in time and resources expended.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 23: Biologics

Biologics is a course of medications in this narrower sense have had a profound impact on many medical fields, primarily rheumatology and oncology, but as well cardiology, dermatology, gastroenterology, neurology, and others. In most of these disciplines, biologics have new major therapeutic options for the treatment of many diseases, including some for which no active therapies were available, and others where previously existing therapies were clearly inadequate. However, the beginning of biologic therapeutics has also raised complex regulatory issues (see below), and significant pharmacoeconomic concerns, because the cost for biologic therapies has been dramatically higher than for conventional (pharmacological) medications. This factor has been particularly relevant since many biological medications are used for the treatment of chronic diseases, such as rheumatoid arthritis or inflammatory bowel disease, or for the treatment of otherwise untreatable cancer during the remainder of life. The cost of treatment with a typical monoclonal antibody therapy for relatively common indications is normally in the range of €7,000–14,000 per patient per year.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 24 : Drug Metabolism

Drug metabolism is also known as xenobiotic metabolism is the biochemical modification of pharmaceutical substances or xenobiotics individually by living organisms, usually through specialized enzymatic systems. Drug metabolism often converts lipophilic chemical compounds into further readily excreted hydrophilic products. The rate of metabolism determines the duration and amount of a drug’s pharmacological action.

Drug metabolism is divided into three phases. In phase I, enzymes such as cytochrome P450 oxidases present reactive or polar groups into xenobiotics. These modified compounds are before conjugated to polar compounds in phase II reactions. These reactions are catalysed by transferase enzymes such as glutathione S-transferases. As a final point, in phase III, the conjugated xenobiotics may be further processed, before being recognised by efflux transporters and driven out of cells.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 25: Drug Discovery Softwares

• 2D/3D QSAR with a vast selection of fingerprint options

• Shape-based screening, with or without atom properties

• Ligand-based pharmacophore demonstrating

• e-Pharmacophore modeling incorporating ligand-receptor interaction energies

• Elastic ligand docking with industry-leading Glide

• Free energy perturbation (FEP) theory

• Linear interaction approximation (LIA)

• Covalent docking

• 2D ligand interaction illustrations

• High-performance QM controls, in gas phase and in solution

• MM/MD simulations, with implicit or explicit solvents

• Small molecule and macromolecular conformational studies

• Mixed-mode QM/MM controls for ground state and reactivity studies

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

Track 26: Mass Spectrometry Drug Discovery

Spectroscopy deals with the study of the communication between matter and electromagnetic radiation, the measurement of radioactivity intensity as a function of wavelength. Spectroscopic techniques utilize the concept of the interaction of light with substance.
The properties of electromagnetic radiation and its interaction with matter leads to variety of types of spectra and accordingly different spectroscopic techniques and their applications. Spectroscopy Journals deal with the various spectroscopies.

Relevant Conferences:

Drug Discovery for Parasitic Diseases, January 24-28, 2016, USA; 7th International Conference on Drug Discovery and Therapy February 15-18, 2016, UAE; Structure Based Drug Design Conference, February 21–24, 2016, USA; 8th International Conference and Exhibition on Pharmaceutics and  Systems March 07-09, 2016, Spain; Drug Discovery and Therapy World Congress May 11-14, 2016, USA; 4th Annual conferences on European Pharma Congress June 13-15, 2016, Germany; 9th World Drug Delivery Summit June 30-July 02, 2016, USA; 7th International conference and exhibition on Pharmacovigilance August 22-24, 2016, Austria; International Conference and Expo on Generic Drug Market and Contract Manufacturing Oct 31- Nov 02, 2016, Spain. The Pharmaceutical and Novel Drug Delivery Healthcare Sciences Society (PHSS), American Associations of pharmaceutical scientists (AAPS), The Pharmaceutical Research & Manufacturers Association (PhRMA), Pharmaceutical Group of European Union (PGEU).

 

Conference series LLC is delighted to invite you to attend the 2nd International Conference and Expo on Drug Discovery & Designing, one of its remarkable Pharmaceutical conferences, to be held during October 27-29, 2016 in Rome, Italy emphasizing on recent areas of more optimized research techniques like rational and computer aided drug designing for the Discovery, Designing and Development of new drugs than by traditional hit and trial method. To know more about Conference series.

Drug Discovery conferences-2016 focuses on discussing the treatment strategies, risk management and consequences and challenges in drug design and discovery industry. Drug Discovery conferences-2016 provides a platform to critically analyze and understand the methods and mechanisms.

Why to attend???

Why to attend???

The Drug Discovery 2016 anticipates participants, renowned speakers and eminent delegates across the globe to be attending the conference to share their valuable presentation and galvanize the scientific community. Scientific people from all over the globe focused on learning about emerging technologies about Drug Discovery and Designing. This is a best globalised opportunity to reach the largest assemblage of participants from the scientific community and research.

Target Audience:

  • Noble laureates
  • Pharmaceutical Researchers
  • Pharmaceutical Industry Professionals (CEOs, MDs, Directors)
  • Academicians (Professors, Deans, Directors,)
  • Pharmaceutical Associations and Societies
  • Young Researchers and Students
  • Post- Doctorals

The European-based pharmaceutical industry makes a major contribution to the Europe, not just in financial terms but also in terms of high-trait employment. Globally Pharma Market ranges from $870-$900 billion and in Europe $260-$280 billion in which Spain market is dominated by branded medicines with a share of about 88% value wise which makes it one of the important destinations with top pharmaceutical companies and renowned associations and it is the 4thlargest pharma­ceutical market in Europe with a mar­ket size of $22.7 billion. The Spanish market registered a Compound Annu­al Growth Rate (CAGR) of ~4.4% during 2007-2011. The revenue of the Spanish generic pharma mar­ket stood at $2.20 billion in 2010, which is expected to reach $7.19 billion in 2017, at a CAGR of 18.4%.

For more details please visit- http://drug-discovery.pharmaceuticalconferences.com/

Why Rome, Italy?

In Italy the pharmaceutical industry creates value through innovation by tapping its potential, the innovative pharmaceutical industry can lead the way in helping Italy achieve its 2023 goals. AIFD is ready to do its part to help the Italian population age healthfully, contribute to national economic growth, and strengthen Itali's global competitiveness by promoting pharmaceutical innovation, R&D,[1]and capital investment. AIFD’s vision is to help create a pharmaceutical industry in Italy that can manufacture higher value-added products, attract globally significant R&D investment, and use advanced technologies to export products on a exponentially greater scale, which will in turn help tip the foreign trade balance in Italy favor.

Conference Highlights:

  • Perspective in Drug Discovery
  • Pharmaceutical Research & Development
  • Drug Designing
  • Bio Markers in Drug Designing
  • Ligand Based Drug Discovery
  • Scaffold Based Drug Discovery
  • Drug Discovery Softwares
  • CNS Drug Discovery
  • GPCR's Drug Discovery
  • Insilico Drug Discovery
  • Chemoinformatics Drug Dsicovery
  • Proteomics Drug Discovery
  • Computational chemistry
  • Computer Aided Drug Designing (CADD)
  • Fragment-Based Drug Discovery
  • An overview of the global markets for drug discovery technologies.
  • Analyses of global market trends, with data from 2012-2014, and projections of CAGRs through 2019.
  • A look at the current state of the drug discovery market, existing platforms and products on the market, and detailed analysis of the competitive environments including new, potential venues for novel technologies and approaches.
  • Descriptions of various products such as bioanalytical instruments, high-throughput screening devices, informatics, and microarrays.
  • Analyses of the main positive and negative factors in each sector of the market, potential future trends, and emerging technologies accross different segments of the industry.

Drug Discovery Assocations:

Alzhimer's Association Research

American Association for Cancer Research(AACR)

Americian Association for Clinical Chemistry(AACC)

Americian Association of Pharmaceutical Scientists (AAPS)

GLOBAL REVENUE OF DRUG DISCOVERY TECHNOLOGIES, BY REGION, 2012-2019


    Fig 1

 

GLOBAL MARKET FOR DRUG DISCOVERY TECHNOLOGIES AND PRODUCTS, 2011-2017


    Fig 2

  • Analyses of global market trends, with data from 2012, estimates for 2013, and projections of compound annual growth rates (CAGRs) through 2018.
  • Examinations of major issues involved in the research and development (R&D) of more effective cell-based approaches, for drug discovery, and absorption, distribution, metabolism, and excretion (ADME)/ toxicity assays in development and in use.
  • Discussion of current issues and trends affecting the industry, and costs and other factors influencing demand.
  • Coverage of new technologies, trends, alliances, and mergers.

GLOBAL MARKET FOR CELL-BASED ASSAYS, 2012–2018


    Fig 3

Welcome Message

by

Dr. George Perry

 

On behalf of the Organizing Committee, I have immense pleasure to note that the OMICS International is organizing the 2nd  International Conference and Expo on Drug Discovery & Designing, October 27-29, 2016 in beautiful city Rome, Italy.

”Within the past few decades, the time and cost of drug development has soared. Today it typically takes about 15 years and costs up to $800 million to convert a promising new compound into a drug on the market. Those costs reflect the complexity of the process. First, scientists must identify the molecule — a target — involved in a disease. That demands an understanding of the metabolic processes of a cell in both its normal and diseased states. A further challenge is the increased demand for drugs focused on chronic degenerative diseases of aging. Not only are these conditions very costly and socially demanding, but successful approaches in curing infectious diseases has left us with few advancements. Understanding how to impact the public health of an aged population will present one the greatest challenges of our century.

Your presence and deliberation will make this congress remarkably successful in all aspects of Drug Discovery.


George Perry, PhD,
Dean, College of Sciences;
The University of Texas at San Antonio, USA

 

To share your views and research, please click here to register for the Conference.

To Collaborate Scientific Professionals around the World

Conference Date October 27-29, 2016
Sponsors & Exhibitors Click here for Sponsorship Opportunities
Speaker Opportunity Closed Day 1 Day 2 Day 3
Poster Opportunity Closed Click Here to View